Autopsy report · NCT00376805

Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer

“Withdrawn due to toxicity”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months after it had already started.
• Ran for about 3 years 9 months before it stopped.
• 6 participants enrolled.
• Results were posted on the registry 7 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Masonic Cancer Center, University of Minnesota

Sponsor type

University, hospital or other

Conditions

Breast Cancer

Interventions

Fludarabine; Cyclophosphamide; Total body irradiation; Natural killer cell infusion; Interleukin-2

Participants

6

Sites

1

Countries

United States

Trials that died the same way

• SMMART Adaptive Clinical Treatment (ACT) Trial
  “Withdrawn due to a change in therapeutic interventions.” (74% match in meaning)
• Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1
  “Withdrawn due to lack of resources” (72% match in meaning)
• Beta Cell Rescue in New Onset Type 1 Diabetes With Efalizumab
  “drug withdrawn from market” (70% match in meaning)
• The Sub-Sero Study
  “Drug supply withdrawn (dec 2019)” (69% match in meaning)
• Lapatinib and Bortezomib in Patients With Advanced Malignancies
  “Drug support withdrawn” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.